Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - Results of a multicentric randomized German trial in advanced head-and-neck cancer

International Journal of Radiation Oncology Biology Physics

Volumn 50, Issue 5, 2001, Pages 1161-1171

  Staar, Susanne ^a   Rudat, Volker ^b   Stuetzer, Hartmut ^a   Dietz, Andreas ^b   Volling, Peter ^c   Schroeder, Michael ^d   Flentje, Michael ^e   Eckel, Hans Edmund ^a   Mueller, Rolf Peter ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF OLDENBURG   (Germany)

^d KLINIKUM KASSEL   (Germany)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Accelerated radiotherapy; G CSF; Head and neck cancer; Radiochemotherapy

Indexed keywords

BIOLOGICAL ORGANS; CHEMOTHERAPY; STATISTICAL METHODS; TOXICITY; TUMORS;

RADIOCHEMOTHERAPY;

RADIOTHERAPY;

CARBOPLATIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE TOXICITY; ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; MOUTH MUCOSA; MUCOSA INFLAMMATION; OROPHARYNX CARCINOMA; PAIN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GERMANY; GRANULOCYTE COLONY-STIMULATING FACTOR; HEAD AND NECK NEOPLASMS; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LIFE TABLES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOTHERAPY, HIGH-ENERGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035424059     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01544-9     Document Type: Article

References (42)

1. Radiation therapy alone or in combination with surgery in head and neck cancer
2. A randomized clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer
3. Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma
4. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy
5. Altered fractionation trials in head and neck cancer
6. Radiotherapy and concurrent chemotherapy: A strategy that improves locoregional control and survival in oropharyngeal cancer
7. Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice?
8. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: A prospective randomized trial
9. Radiation alone versus radiation plus weekly low-dose cisplatinum in unresectable cancer of the head and neck
10. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer
11. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer
12. Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy
13. Meta-analysis in head and neck squamous cell carcinoma. What is the role of chemotherapy?
14. The hazard of accelerated tumor clonogen repopulation during radiotherapy
15. Accelerated fractionation in the radiation treatment of head and neck cancer
16. The linear-quadratic formula and program in fractionated radiotherapy
17. Randomized clinical trial of accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on therapy toxicity
18. Conventional radiotherapy as the primary treatment of squamous cell carcinoma (SCC) of the head and neck. A randomized multicenter study of 5 versus 6 fractions per week - Preliminary report from DAHANCA 6 and 7 trial
19. A randomized trial of accelerated versus conventional radiotherapy in head and neck cancer
20. Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx
21. Results of a German multicentric trial of accelerated hyperfractionated radiochemotherapy in advanced head and neck cancer
22. Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients
23. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
24. Interdisciplinary documentation of treatment side effects in oncolgy. Present status and perspectives
25. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale mitomycin randomized trials
26. A cooperative AIRO/Piemonte randomized clinical trial of carboplatin as an adjunct to radiotherapy in head and neck cancer
27. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy (RT) alone in resectable stage III and IV squamous cell head and neck cancer (SCHNC)
28. Randomized trial of radiation therapy versus concomitant chemoradiotherapy and radiation therapy for advanced advanced-stage oropharynx carcinoma
29. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation, and two variants of accelerated fractionation to standard fractionation radiotherapy for head, and neck suqamous cell carcinoma. Preliminary results of RTOG 9003
30. Concurrent platinum-based chemotherapy and hyperfractionated radiotherapy with late intensification in advanced head and neck cancer
31. Accelerated radiotherapy with delayed concomitant boost in locally advanced squamous cell carcinoma of the head and neck
32. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study
33. Continuous hyperfractionated accelerated radiotherapy and mitomycin C in head and neck cancer
34. Concomitant chemoradiotherapy as primary therapy for locoregional advanced head and neck cancer
35. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanved head and neck cancer
36. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognostic head and neck cancer
37. Expression of granulocyte colony-stimulating factor receptor correlates with prognosis in oral and mesopharyngeal carcinoma
38. Granulocyte-colony-stimulating factor enhances invasive potential of human head-and-neck-carcinoma cell lines
39. SMART (Simultaneous Modulated Accelerated Radiation Therapy Boost). A new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy